Efficient Serum-Free Rabies Virus Propagation Using BSR and Vero Cell Lines: A Comparative Evaluation of BioNOC II® Macrocarriers in the BelloStage™-3000 Bioreactor Versus Conventional Microcarriers
The rabies virus remains a significant public health threat, particularly in regions with limited access to vaccination. This study shows that the BelloStage™-3000 bioreactor, operating on the "Tide Motion" principle, in combination with BioNOC<sup>®</sup> II macrocarriers, ensures highly efficient rabies virus cultivation in BSR and Vero cells grown in serum-free OptiPRO™ SFM medium. This system supports effective cell attachment, formation of a dense and metabolically active cell layer, and reduces microbial contamination risks associated with serum-containing media. For comparison, rabies virus cultivation was also performed on Cytodex 1 and Cytodex 3 microcarriers in spinner flasks. The use of the BelloStage™-3000 bioreactor system with BelloCell™ 500A disposable vials and BioNOC II<sup>®</sup> macrocarriers resulted in significantly higher virus titers compared to traditional Cytodex 1 and Cytodex 3 microcarrier culture systems. Thus, in the BSR cell culture, the maximum virus titer reached 5.6 × 10<sup>8</sup> FFU/mL by day 4 of cultivation, which exceeded the titers obtained on Cytodex 1 and Cytodex 3 microcarriers by about 19.3-fold and 15.3-fold, respectively. A similar trend was observed for the Vero cell line: the peak titer was 2.0 × 10<sup>8</sup> FFU/mL by day 5 of culturing, which was higher than the values obtained on Cytodex 1 and Cytodex 3 by about 14.0-fold and 9.6-fold, respectively. These findings demonstrate that the integrated use of BioNOC<sup>®</sup> II macrocarriers, the BelloStage™-3000 bioreactor, and a serum-free medium provides a scalable, reproducible, and biosafe platform for rabies virus production, offering substantial advantages over traditional microcarrier-based systems.
Authors
- Ruslan Abitayev (ORCID: https://orcid.org/0000-0001-5609-2491)
- Yerbol A. Bulatov (ORCID: https://orcid.org/0000-0001-8543-4219)
- Dariya Toktyrova (ORCID: https://orcid.org/0000-0003-3166-4515)
- Abdurakhman Ussembay (ORCID: https://orcid.org/0000-0003-3639-3793)
- Алина Курмашева (ORCID: https://orcid.org/0009-0008-9484-0540)
- Саметова Жанна Жумабековна (ORCID: https://orcid.org/0000-0002-2332-2841)
- Sh. S. Turyskeldі (ORCID: https://orcid.org/0000-0002-9515-0655)
- Aslan Kerimbayev (ORCID: https://orcid.org/0000-0002-9387-6647)
- Sergazy Sh. Nurabayev (ORCID: https://orcid.org/0000-0003-0843-1983)
- Аманова Жанат Темирбаевна (ORCID: https://orcid.org/0000-0002-3987-6814)
- Zhanat Kondybaeva (ORCID: https://orcid.org/0000-0002-8224-8047)
- Dana Mazbayeva (ORCID: https://orcid.org/0009-0002-3892-0032)
Institutions
- Institute of Informatics Problems (RU)
- National Center for Biotechnology (KZ)
Publication Details
- Journal
- Biology
- Published
- 2025-10-21
- DOI
- https://doi.org/10.3390/biology14101455
- Primary Topic
- Virus-based gene therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00